Kolon Corporation (002020) Q4 2024 earnings summary

Executive summary

• Consolidated revenue for FY2024 was KRW 6,028.4 billion, up 2.6% year-over-year, with a net profit of KRW 157.6 billion, a significant increase from the prior year.

• Operating loss was KRW 89.6 billion, reversing from an operating profit of KRW 99.3 billion in FY2023.

• Major business combinations included the acquisition of Kolon TissueGene and Kolon Spaceworks, and several business segment restructurings.

• The group continued to focus on its holding company structure, with key subsidiaries in construction, mobility, IT, pharma, and bio sectors.

Financial highlights

• Revenue: KRW 6,028.4 billion (+2.6% YoY); Operating loss: KRW 89.6 billion (from profit in FY2023); Net profit: KRW 157.6 billion (+924.4% YoY).

• Gross profit margin decreased due to higher cost of sales and increased SG&A expenses.

• Cash and cash equivalents at year-end: KRW 350.9 billion.

• Total assets: KRW 7,040.5 billion; Total liabilities: KRW 4,692.6 billion; Total equity: KRW 2,347.8 billion.

• Dividend per share: KRW 550 (common), KRW 600 (preferred).

Outlook and guidance

• The group aims to enhance shareholder value through efficient capital allocation and continued investment in core and growth businesses.

• Focus remains on strengthening the holding company structure and expanding in high-growth sectors such as bio and IT.

• Dividend policy targets payout of at least 40% of separate net income (excluding one-off items).